OBI filed the application of Phase III human clinical study for the active cancer immunotherapy OBI-822, Adagloxad Simolenin, to the drug administrations in Argentina, Brazil, and South Africa
2021.Jan.26
Mr. Michael Chang and five other executives received an acquittal for insider trading case at second instance by Taiwan High Court
2021.Jan.06
OBI Pharma Inc. to attend the 39th Annual J.P. Morgan Healthcare Conference
2020.Dec.30
OBI capital increases by issuance of stocks to transfer stocks with Amaran Biotechnology Inc. (Announcement of base day and trading counterparty)
2020.Dec.25
The active cancer immunotherapy OBI-822, Adagloxad Simolenin, has been granted by National Medical Products Administration (NMPA) to proceed Phase III human clinical study
2020.Dec.14
OBI Pharma Inc. to attend Investor Conference hosted by Masterlink Securities
2020.Dec.04
OBI licensed the Intellectual Property Right of Global Aesthetic Medicine to a designated company
2020.Nov.27
OBI capital increases by issuance of stocks to transfer stocks with Amaran Biotechnology Inc. (supplement base date)
2020.Nov.23
OBI received the reply from FDA about the Investigational Device Exemption (IDE) of Phase I/II Cohort Expansion human clinical studies for first-in-class novel prodrug, OBI-3424
2020.Nov.06
Announcement of 2020 Q3 financial reports submitted to the board of directors
